Zhejiang Hisun Pharmaceutical Co.

Taizhou, China

Zhejiang Hisun Pharmaceutical Co.

Taizhou, China
SEARCH FILTERS
Time filter
Source Type

Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-05-17

A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-01-18

The present invention relates to a recombinant microorganism expressing avermectin or analogues thereof and construction method thereof, and also relates to a method of producing avermectin or analogues thereof using the recombinant microorganism, and avermectin or analogues thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogues thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogues thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-01-11

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2 diffraction angles: 5.70.2, 6.20.2, 11.20.2, 12.40.2, 18.20.2, 21.40.2, 21.80.2 and 23.60.2; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2 diffraction angles: 6.00.2, 11.80.2, 18.20.2, 21.60.2, 24.40.2, 27.70.2 and 29.70.2. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.


Patent
Zhejiang Hisun Pharmaceutical Co. and Zhejiang Hisun Chemical Co. | Date: 2017-01-18

A sixteen-membered macrolide compound and use thereof, the compound structure being represented in formula (I), wherein R is CH_(3) or C_(2)H_(5). The present compound has a wide range of application in the preparation of chemicals for preventing and controlling insect pests and mites of agriculture and forestry.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2015-03-04

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2 diffraction angles: 5.70.2, 6.20.2, 11.20.2, 12.40.2, 18.20.2, 21.40.2, 21.80.2 and 23.60.2; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 20 diffraction angles: 6.00.2, 11.80.2, 18.20.2, 21.60.2, 24.40.2, 27.70.2 and 29.70.2. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2015-06-05

Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production.


Patent
Zhejiang Hisun Pharmaceutical Co. and Zhejiang Hisun Chemical Co. | Date: 2015-03-10

A sixteen-membered macrolide compound and use thereof, the compound structure being represented in formula (I), wherein R is CH_(3 )or C_(2)H_(5). The present compound has a wide range of application in the preparation of chemicals for preventing and controlling insect pests and mites of agriculture and forestry.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-12-21

The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-12-21

The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-04-12

Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production.

Loading Zhejiang Hisun Pharmaceutical Co. collaborators
Loading Zhejiang Hisun Pharmaceutical Co. collaborators